

OBJECTIVE

Clinicians in Alberta select optimal laboratory tests for investigation of suspected acromegaly

TARGET POPULATION

Any person with signs or symptoms of acromegaly

EXCLUSIONS

None

RECOMMENDATIONS

- ✓ Measure fasting insulin-like growth factor 1 (IGF-1) to diagnose acromegaly
- ✓ Repeat test if result is borderline
- ✓ Refer to endocrinologist as soon as possible if acromegaly is suspected

Acromegaly Clinical Features

Those resulting from the mass effects of the enlarging tumor:

- Headaches
- Visual field defects
- Hypopituitarism

Those resulting from hormone over secretion:

- Coarse facial features
- Acral overgrowth (e.g., increasing glove, hat, ring, shoe sizes)
- Soft tissue change (e.g., skin tags)
- Hyperhidrosis

- Glucose intolerance
- Neuropathy
- Arthritis
- Sleep apnea

BACKGROUND

Acromegaly is a chronic debilitating condition that is usually the result of a growth hormone secreting pituitary adenoma. Epidemiologic studies have suggested an incidence of three to four per million with a prevalence of 68 to 80 cases per million.^{1,2}

Serum IGF-1 detects nearly all cases of acromegaly and correlates with the clinical activity of the disease.³⁻⁵ Acromegaly must be diagnosed with endocrine investigation prior to radiologic examinations.

These recommendations are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. They should be used as an adjunct to sound clinical decision making.



REFERENCES

- 1. Melmed S, Ho K, Klibanski A, et al. Recent advances in pathogenesis, diagnosis and management of acromegaly. J Clin Endocrinol Metab, 1995;80:3395-3402.
- 2. Ezzat S, Wilkins G, Patel Y, et al. The diagnosis and management of acromegaly: a Canadian consensus report. Clin Invest Med, 1996;19:259-70.
- 3. Clemmons DR, Van Wyk JJ, Ridgway EC, et al. Evaluation of acromegaly by radioimmunoassay of somatomedin C. N Engl J Med, 1979;301:1138-42.
- 4. Roelfsma F, Frolich M, Van Dulken H. Somato- medin-C levels in treated and untreated patients with acromegaly. Clin Endocrinol (Oxf), 1978;26:1137-44.
- Hartman ML, Veldhuis JD, Vance ML, et al. Somatotropin pulse frequency and basal concentrations are increased in acromegaly and are reduced by successful therapy. J Clin Endocrinol Metab, 1990;7:1375-84.

SUGGESTED CITATION

Toward Optimized Practice (TOP) Endocrine Working Group. 2008 January. Laboratory endocrine testing: acromegaly clinical practice guideline. Edmonton, AB: Toward Optimized Practice. Available from: http://www.topalbertadoctors.org

For more information see www.topalbertadoctors.org

GUIDELINE COMMITTEE

The committee consisted of representatives of family medicine, general medicine, medical biochemistry, pathology, internal medicine, endocrinology, laboratory technologists and the public.

April 1998 Revised June 2001 Reviewed January 2008 Reviewed May 2014